The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Oral DNA vaccination targeting VEGFR2 combined with anti-PDL1 avelumab in patients with progressive glioblastoma: Safety run-in results—NCT03750071.
 
Wolfgang Wick
Consulting or Advisory Role - Abbvie; MSD Oncology (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst)
Research Funding - Apogenix (Inst); Pfizer (Inst); Roche (Inst)
 
Antje Wick
No Relationships to Disclose
 
Olivier L. Chinot
No Relationships to Disclose
 
Martin J. Van Den Bent
Consulting or Advisory Role - Abbvie; Agios; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; carthera; Celgene; Daiichi Sankyo; Genenta Science; Nerviano Medical Sciences
Research Funding - Abbvie (Inst)
 
Filip Yves Francine Leon De Vos
Research Funding - Abbvie (Inst); BioClin Therapeutics (Inst); Novartis (Inst)
Expert Testimony - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Roche/Genentech
 
Marc Mansour
Employment - VAXIMM
Leadership - VAXIMM
Stock and Other Ownership Interests - VAXIMM
Honoraria - VAXIMM
Consulting or Advisory Role - AELIX Therapeutics; Leidos
Research Funding - VAXIMM (Inst)
 
Lilli Podola
Employment - VAXIMM
 
Heinz Lubenau
Leadership - VAXIMM
Stock and Other Ownership Interests - VAXIMM
Honoraria - VAXIMM
Patents, Royalties, Other Intellectual Property - VAXIMM
Travel, Accommodations, Expenses - VAXIMM
 
Michael Platten
No Relationships to Disclose